BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 10879106)

  • 1. [Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors].
    Hamazaki T; Yagi K; Inoue M; Sakata N; Okamura T; Yasui M; Sasabe M; Kishimoto T; Inoue A; Kawa K
    Rinsho Ketsueki; 2000 May; 41(5):430-6. PubMed ID: 10879106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [FK506 for the prophylaxis of graft-versus-host-disease after bone marrow transplantation from HLA-genotypically mismatched unrelated donor].
    Nishida T; Haneda M; Kanie T; Murata M; Hamaguchi M; Minami S; Kodera Y
    Rinsho Ketsueki; 1998 Aug; 39(8):574-9. PubMed ID: 9785975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis.
    Yagasaki H; Kojima S; Yabe H; Kato K; Kigasawa H; Sakamaki H; Tsuchida M; Kato S; Kawase T; Muramatsu H; Morishima Y; Kodera Y
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1603-8. PubMed ID: 19896085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies.
    Uberti JP; Silver SM; Adams PT; Jacobson P; Scalzo A; Ratanatharathorn V
    Bone Marrow Transplant; 1997 Jun; 19(12):1233-8. PubMed ID: 9208118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Allogeneic bone marrow transplantation in children from related donors other than HLA-identical siblings].
    Morimoto T; Hattori K; Yabe H; Yabe M; Hinohara T; Shimizu T; Matsumoto M; Hagihara M; Tsuji K; Kato S
    Rinsho Ketsueki; 1998 Sep; 39(9):631-9. PubMed ID: 9796395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation.
    Yanik G; Levine JE; Ratanatharathorn V; Dunn R; Ferrara J; Hutchinson RJ
    Bone Marrow Transplant; 2000 Jul; 26(2):161-7. PubMed ID: 10918426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unrelated donor bone marrow transplantation for 100 pediatric patients: a single institute's experience.
    Yumura-Yagi K; Inoue M; Sakata N; Okamura T; Yasui M; Sawada A; Sato E; Chayama K; Endo C; Sasabe M; Miyamura T; Park YD; Nakano T; Inagaki J; Kishimoto T; Nomura K; Saito I; Hamada S; Nakano T; Hashii Y; Kawa K
    Bone Marrow Transplant; 2005 Aug; 36(4):307-13. PubMed ID: 15968285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation.
    Ogawa H; Soma T; Hosen N; Tatekawa T; Tsuboi A; Oji Y; Tamaki H; Kawakami M; Ikegame K; Murakami M; Fujioka T; Kim EH; Oka Y; Sugiyama H
    Transplantation; 2002 Jul; 74(2):236-43. PubMed ID: 12151737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
    Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease.
    Gondo H; Harada M; Taniguchi S; Akashi K; Hayashi S; Teshima T; Takamatsu Y; Eto T; Nagafuji K; Yamasaki K
    Bone Marrow Transplant; 1993 Nov; 12(5):437-41. PubMed ID: 8298553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone.
    Leelasiri A; Greer JP; Stein RS; Goodman S; Brandt SA; Edwards JR; Wolff SN
    Bone Marrow Transplant; 1995 Mar; 15(3):401-5. PubMed ID: 7599565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity.
    Bertz H; Potthoff K; Mertelsmann R; Finke J
    Bone Marrow Transplant; 1997 Jun; 19(12):1169-73. PubMed ID: 9208109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease.
    Kumar S; Wolf RC; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Litzow MR
    Bone Marrow Transplant; 2002 Aug; 30(3):161-5. PubMed ID: 12189534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG].
    Graf Finckenstein F; Zabelina T; Dürken M; Dahlke J; Kröger N; Krüger W; Janka-Schaub G; Erttmann R; Zander AR; Kabisch H
    Klin Padiatr; 2002; 214(4):206-11. PubMed ID: 12165903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
    Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
    Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y; Nagatoshi Y; Kawano Y; Okamura J
    Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of steroid-resistant severe acute GVHD with 24-h continuous infusion of FK506.
    Ohashi Y; Minegishi M; Fujie H; Tsuchiya S; Konno T
    Bone Marrow Transplant; 1997 Mar; 19(6):625-7. PubMed ID: 9085743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation.
    Yu C; Storb R; Deeg HJ; Graham TC; Scheuning FG; Huss R; Seidel K; Fitzsimmons WE
    Bone Marrow Transplant; 1996 Apr; 17(4):649-53. PubMed ID: 8722370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.